Table 4 The difference of efficacy, according to LDH—elevated LDH at baseline, 16 and 32 weeks showed inadequate treatment response in EASI.

From: A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world

 

LDH at baseline

LDH at 16 weeks

LDH at 32 weeks

LDH at 52 weeks

 < 250 (n = 30)

 ≥ 250 (n = 43)

 < 250 (n = 66)

 ≥ 250 (n = 22)

 < 250 (n = 63)

 ≥ 250 (n = 21)

 < 250 (n = 65)

 ≥ 250 (n = 6)

Percent change of EASI after 52 weeks

90.50

85.55

89.42

84.49

90.75

82.49

89.32

78.60

p value*

 

0.014

 

0.046

 

 < 0.001

 

0.052

Percent change of NRS after 52 weeks

70.29

62.63

68.36

57.69

70.46

59.37

69.18

47.22

p value*

 

0.194

 

0.067

 

0.052

 

0.003

Percent change of POEM after 52 weeks

67.62

66.85

68.76

67.10

71.22

68.06

70.87

36.13

p value*

 

0.920

 

0.793

 

0.576

 

 < 0.001

Percent change of DLQI after 52 weeks

72.78

65.38

70.22

63.33

74.16

61.82

73.49

46.98

p value*

 

0.315

 

0.260

 

0.058

 

0.013

  1. *p values were obtained by two sample independent t-test.
Back to article page